Epiomic Epidemiology Series: Gastro Oesophageal Reflux Disease Forecast in 19 Major Markets 2017-2027

September 2017 | 42 pages | ID: E2C7466D830EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Gastro-Oesophageal Reflux Disease in 19 Major Markets

Gastro-oesophageal reflux disease (GORD) is a common disorder of the upper gastrointestinal tract. According to the most recent definition, it is a condition occurring when reflux of gastric contents causes troublesome symptoms and/or complications. Based on endoscopy findings, the disease is broadly classified into two subtypes: demonstrating oesophageal mucosal damage (Erosive Reflux Disease, ERD) or no mucosal damage (Non-Erosive Reflux Disease, NERD). Injury to the oesophagus that may be associated with GORD is due to reflux of gastric acid and pepsin, but also bile in the case of duodenogastric reflux.

This report provides the current prevalent population for GORD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Norway, Sweden, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, the two subtypes of the disease (ERD and NERD), as well as several of the main symptoms and co-morbidities of GORD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GORD include:

• Globus
• Non-cardiac chest pain
• Asthma
• Dysphagia
• Dyspepsia
• Chronic cough

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global GORD market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of GORD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on GORD prevalent population.
• Identify sub-populations within GORD which require treatment.
• Gain an understanding of the specific markets that have the largest number of GORD patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR GASTRO-OESOPHAGEAL REFLUX DISEASE

FEATURES OF GASTRO-OESOPHAGEAL REFLUX DISEASE PATIENTS

COMORBID CONDITIONS OF GORD PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN ANALYSIS PUBLICATIONS

BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

PATIENT-BASED OFFERING

ONLINE PRICING DATA & PLATFORMS

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Modified Savary–Miller and Los Angeles classification systems
Table 2. Prevalence of GORD, total (000s)
Table 3. Prevalence of GORD, males (000s)
Table 4. Prevalence of GORD, females (000s)
Table 5. Prevalence of Erosive Reflux Disease by Sex (000s)
Table 6. Prevalence of Non-Erosive Reflux Disease by Sex (000s)
Table 7. GORD Patients with Globus, total (000s)
Table 8. GORD Patients with Non-cardiac Chest Pain, total (000s)
Table 9. GORD Patients with Hoarseness, total (000s)
Table 10. GORD Patients with Asthma, total (000s)
Table 11. GORD Patients with Dysphagia, total (000s)
Table 12. GORD Patients with Dyspepsia, total (000s)
Table 13. GORD Patients with Chronic Cough, total (000s)
Table 14. Abbreviations and Acronyms used in the report
Table 15. USA Prevalence of GORD by 5-yr age cohort, males (000s)
Table 16. USA Prevalence of GORD by 5-yr age cohort, females (000s)
Table 17. Canada Prevalence of GORD by 5-yr age cohort, males (000s)
Table 18. Canada Prevalence of GORD by 5-yr age cohort, females (000s)
Table 19. France Prevalence of GORD by 5-yr age cohort, males (000s)
Table 20. France Prevalence of GORD by 5-yr age cohort, females (000s)
Table 21. Germany Prevalence of GORD by 5-yr age cohort, males (000s)
Table 22. Germany Prevalence of GORD by 5-yr age cohort, females (000s)
Table 23. Italy Prevalence of GORD by 5-yr age cohort, males (000s)
Table 24. Italy Prevalence of GORD by 5-yr age cohort, females (000s)
Table 25. Spain Prevalence of GORD by 5-yr age cohort, males (000s)
Table 26. Spain Prevalence of GORD by 5-yr age cohort, females (000s)
Table 27. UK Prevalence of GORD by 5-yr age cohort, males (000s)
Table 28. UK Prevalence of GORD by 5-yr age cohort, females (000s)
Table 29. Russia Prevalence of GORD by 5-yr age cohort, males (000s)
Table 30. Russia Prevalence of GORD by 5-yr age cohort, females (000s)
Table 31. Norway Prevalence of GORD by 5-yr age cohort, males (000s)
Table 32. Norway Prevalence of GORD by 5-yr age cohort, females (000s)
Table 33. Sweden Prevalence of GORD by 5-yr age cohort, males (000s)
Table 34. Sweden Prevalence of GORD by 5-yr age cohort, females (000s)
Table 35. Turkey Prevalence of GORD by 5-yr age cohort, males (000s)
Table 36. Turkey Prevalence of GORD by 5-yr age cohort, females (000s)
Table 37. Japan Prevalence of GORD by 5-yr age cohort, males (000s)
Table 38. Japan Prevalence of GORD by 5-yr age cohort, females (000s)
Table 39. China Prevalence of GORD by 5-yr age cohort, males (000s)
Table 40. China Prevalence of GORD by 5-yr age cohort, females (000s)
Table 41. South Korea Prevalence of GORD by 5-yr age cohort, males (000s)
Table 42. South Korea Prevalence of GORD by 5-yr age cohort, females (000s)
Table 43. India Prevalence of GORD by 5-yr age cohort, males (000s)
Table 44. India Prevalence of GORD by 5-yr age cohort, females (000s)
Table 45. Australia Prevalence of GORD by 5-yr age cohort, males (000s)
Table 46. Australia Prevalence of GORD by 5-yr age cohort, females (000s)
Table 47. Brazil Prevalence of GORD by 5-yr age cohort, males (000s)
Table 48. Brazil Prevalence of GORD by 5-yr age cohort, females (000s)
Table 49. Mexico Prevalence of GORD by 5-yr age cohort, males (000s)
Table 50. Mexico Prevalence of GORD by 5-yr age cohort, females (000s)
Table 51. Argentina Prevalence of GORD by 5-yr age cohort, males (000s)
Table 52. Argentina Prevalence of GORD by 5-yr age cohort, females (000s)